Skip to main content
SpringerLink
Log in

Quantification of Alpha-Synuclein in Biological Fluids by Electrochemiluminescence-Based Detection

  • Protocol
  • First Online:
Alpha-Synuclein

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1948))

Abstract

Several potential marker candidates for Parkinson’s disease (PD) in cerebrospinal fluid (CSF) have been identified. These include α-synuclein, a major constituent of the intracellular aggregates Lewy bodies, a neuropathological hallmark of PD, and others. The extracellular presence of α-synuclein in blood, CSF, saliva, and conditioned media motivated the hypothesis that the quantification of CSF α-synuclein is a biomarker for α-synuclein-related disorders. We here describe the development of an electrochemiluminescence-based assay by conversion of an established ELISA for quantification of α-synuclein. The assay not only works with CSF but can also be used to quantify α-synuclein in different biological fluids, i.e., whole blood and blood products, saliva, as well as brain homogenates and cell culture material.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lee JW, Weiner RS, Sailstad JM, Bowsher RR, Knuth DW, O’Brien PJ, Fourcroy JL, Dixit R, Pandite L, Pietrusko RG, Soares HD, Quarmby V, Vesterqvist OL, Potter DM, Witliff JL, Fritche HA, O’Leary T, Perlee L, Kadam S, Wagner JA (2005) Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res 22:499–511

    Article  CAS  Google Scholar 

  2. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R et al (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38:643–648

    Article  CAS  Google Scholar 

  3. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C et al (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359:325–327

    Article  CAS  Google Scholar 

  4. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Schelters P (2010) Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 9:1118–1127

    Article  Google Scholar 

  5. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:263–269

    Article  Google Scholar 

  6. Dieterle F, Marrer E (2008) New technologies around biomarkers and their interplay with drug development. Anal Bioanal Chem 390:141–154

    Article  CAS  Google Scholar 

  7. Lewczuk P, Wiltfang J (2008) Neurochemical dementia diagnostics: State of the art and research perspectives. Proteomics 8:1292–1301

    Article  CAS  Google Scholar 

  8. Gerlach M, Maetzler W, Broich K, Hampel H, Rems L, Reum T, Riederer P, Stoffler A, Streffer J, Berg D (2012) Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm 119:39–52

    Article  CAS  Google Scholar 

  9. Steemers FJ, Gunderson KL (2007) Whole genome genotyping technologies on the BeadArray platform. Biotechnol J 2:41–49

    Article  CAS  Google Scholar 

  10. Abramovitz M, Barwick BG, Willis S, Young B, Catzavelos C, Li Z, Kodani M, Tang W, Bouzyk M, Moreno CS, Leyland-Jones B (2011) Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform. Br J Cancer 105:1574–1581

    Article  CAS  Google Scholar 

  11. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, Zhang J (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69:570–580

    Article  CAS  Google Scholar 

  12. Cotte S, von Ahsen N, Kruse N, Huber B, Winkelmann A, Zettl UK, Starck M, Konig N, Tellez N, Dorr J, Paul F, Zipp F, Luhder F, Koepsell H, Pannek H, Montalban X, Gold R, Chan A (2009) ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 132:2517–2530

    Article  CAS  Google Scholar 

  13. Kruse N, Pette M, Toyka K, Rieckmann P (1997) Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. J Immunol Methods 210:195–203

    Article  CAS  Google Scholar 

  14. Trune DR, Larrain BE, Hausman FA, Kempton JB, MacArthur CJ (2011) Simultaneous measurement of multiple ear proteins with multiplex ELISA assays. Hear Res 275:1–7

    Article  CAS  Google Scholar 

  15. Roberts R, Stewart AFR, Wells GA, Williams KA, Kavaslar N, McPherson R (2007) Can J Cardiol (Suppl. A);7A–15A

    Google Scholar 

  16. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ, El-Agnaf OM, Schlossmacher MG (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213:315–325

    Article  CAS  Google Scholar 

  17. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG (2011) alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10:230–240

    Article  CAS  Google Scholar 

  18. Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG (2010) Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. BiomarkMed 4:683–699

    CAS  Google Scholar 

  19. Kruse N, Schulz-Schaeffer WJ, Schlossmacher MG, Mollenhauer B (2012) Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of alpha-synuclein and other proteins in cerebrospinal fluid. Methods 56:514–518

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The authors want to thank Sabine Lange for helpful discussions and advice. Omar el-Agnaf and Liyu Wu provided us kindly with α-synuclein standards and antibody MJFR1. We thank Omar El-Agnaf and Michael Schlossmacher who developed the first prototype ELISA assay and Walter Schulz-Schaeffer for his fruitful input.

Author information

Authors and Affiliations

  1. Institute of Neuropathology, University Medical Center Göttingen, Göttingen, Germany

    Niels Kruse

  2. Paracelsus-Elena-Klinik, Kassel, Germany

    Brit Mollenhauer

  3. Department of Neurology, University Medical Center Göttingen, Göttingen, Germany

    Brit Mollenhauer

Authors
  1. Niels Kruse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brit Mollenhauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brit Mollenhauer .

Editor information

Editors and Affiliations

  1. Dementia Research Institute, University College London, London, UK

    Tim Bartels

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Kruse, N., Mollenhauer, B. (2019). Quantification of Alpha-Synuclein in Biological Fluids by Electrochemiluminescence-Based Detection. In: Bartels, T. (eds) Alpha-Synuclein. Methods in Molecular Biology, vol 1948. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-9124-2_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-9124-2_6

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-9123-5

  • Online ISBN: 978-1-4939-9124-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation